Pseudotyping viral vectors with emerging virus envelope proteins

Current Gene Therapy

Volumn 16, Issue 1, 2016, Pages 47-55

  Steffen, Imke ^a,b   Simmons, Graham ^a,b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug screening; Emerging viruses; Enveloped viruses; Lentiviral vectors; Pseudotypes; Rhabdoviral vectors; Serology

Indexed keywords

FOLATE RECEPTOR 1; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; VIRUS PROTEIN; VIRUS VECTOR; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ARTICLE; CHIKUNGUNYA VIRUS; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; DRUG SCREENING; EBOLAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; HEMORRHAGIC FEVER; HEPATITIS C VIRUS; HUMAN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NIEMANN PICK DISEASE; NIPAH VIRUS; NONHUMAN; PSEUDOTYPING; ROSS RIVER VIRUS; SARS CORONAVIRUS; SCHISTOSOMIASIS MANSONI; TRYPANOSOMA CRUZI; VACCINATION; VESICULOVIRUS; VIRAL TROPISM; VIRUS NEUTRALIZATION; VIRUS REPLICATION; CORONAVIRIDAE; GENE VECTOR; GENETICS; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANTIBODIES, NEUTRALIZING; CORONAVIRUS; DRUG EVALUATION, PRECLINICAL; EBOLAVIRUS; GENETIC THERAPY; GENETIC VECTORS; NIPAH VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL TROPISM; VIRAL VACCINES;

EID: 84958979669     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523216666160119093948     Document Type: Article

References (83)

1. Clapham PR. Vesicular stomatitis virus pseudotypes of retroviruses. Methods Mol Biol 1992; 8: 95-102.
2. Simmons G, McKnight A, Takeuchi Y, et al. Cell-to-cell fusion, but not virus entry in macrophages by T-cell line tropic HIV-1 strains: a V3 loop-determined restriction. Virology 1995; 209(2): 696-700.
3. Sanders DA. No false start for novel pseudotyped vectors. Curr Opin Biotechnol 2002;13(5):437-42.
4. Sandrin V, Cosset FL. Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein. J Biol Chem 2006; 281(1): 528-42.
5. Grard G, Fair JN, Lee D, et al. A novel rhabdovirus associated with acute hemorrhagic fever in central Africa. PLoS Pathog 2012; 8(9): e1002924.
6. Steffen I, Liss NM, Schneider BS, et al. Characterization of the Bas-Congo virus glycoprotein and its function in pseudotyped viruses. J Virol 2013; 87(17): 9558-68.
7. Kolokoltsov AA, Weaver SC, Davey RA. Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins. J Virol 2005; 79(2): 756-63.
8. Salvador B, Zhou Y, Michault A, et al. Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology 2009; 393(1): 33-41.
9. Sharkey CM, North CL, Kuhn RJ, et al. Ross River virus glycoprotein- pseudotyped retroviruses and stable cell lines for their production. J Virol 2001; 75(6): 2653-9.
10. Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446(7137): 801-5.
11. Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457(7231): 882-6.
12. Chan SY, Empig CJ, Welte FJ, et al. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 2001; 106(1): 117-26.
13. Sinn PL, Hickey MA, Staber PD, et al. Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J Virol 2003; 77(10): 5902-10.
14. Simmons G, Rennekamp AJ, Chai N, et al. Folate receptor alpha and caveolae are not required for Ebola virus glycoproteinmediated viral infection. J Virol 2003; 77(24): 13433-8.
15. Carette JE, Raaben M, Wong AC, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011; 477(7364): 340-3.
16. Cote M, Misasi J, Ren T, et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011; 477(7364): 344-8.
17. Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol 1998; 72(4): 3155-60.
18. Palomares K, Vigant F, Van Handel B, et al. Nipah virus envelopepseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo. J Virol 2013; 87(4): 2094-108.
19. Fields BN, Hawkins K. Human infection with the virus of vesicular stomatitis during an epizootic. N Engl J Med 1967; 277(19): 989- 94.
20. Webb PA, Monath TP, Reif JS, et al. Epizootic vesicular stomatitis in Colorado, 1982: epidemiologic studies along the northern Colorado front range. J Am Trop Med Hyg 1987; 36(1): 183-8.
21. Kobinger GP, Limberis MP, Somanathan S, et al. Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells. Hum Gene Ther 2007; 18(5): 413-22.
22. Kobinger GP, Weiner DJ, Yu QC, et al. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001; 19(3): 225-30.
23. Trabalza A, Georgiadis C, Eleftheriadou I, et al. Venezuelan equine encephalitis virus glycoprotein pseudotyping confers neurotropism to lentiviral vectors. Gene Ther 2013; 20(7): 723-32.
24. Lee AM, Pasquato A, Kunz S. Novel approaches in anti-arenaviral drug development. Virology 2011; 411(2): 163-9.
25. Zhou Y, Simmons G. Development of novel entry inhibitors targeting emerging viruses. Expert Rev Anti Infect Ther 2012; 10(10): 1129-38.
26. Wolf MC, Freiberg AN, Zhang T, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci USA 2010; 107(7): 3157-62.
27. Vigant F, Lee J, Hollmann A, et al. A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog 2013; 9(4): e1003297.
28. Zhou Y, Agudelo J, Lu K, et al. Inhibitors of SARS-CoV entryidentification using an internally-controlled dual envelope pseudovirion assay. Antiviral Res 2011; 92(2): 187-94.
29. Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 2015; 116C: 76-84.
30. Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 2005; 102(33): 11876-81.
31. Abdulla MH, Lim KC, Sajid M, et al. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med 2007; 4(1): e14.
32. Engel JC, Doyle PS, Hsieh I, et al. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 1998; 188(4): 725-34.
33. Thorstensson R, Andersson S, Lindback S, et al. Evaluation of 14 commercial HIV-1/HIV-2 antibody assays using serum panels of different geographical origin and clinical stage including a unique seroconversion panel. J Virol Methods 1998; 70(2): 139-51.
34. Wallerstrom S, Lagerqvist N, Temperton NJ, et al. Detection of antibodies against H5 and H7 strains in birds: evaluation of influenza pseudovirus particle neutralization tests. Infect Ecol Epidemiol 2014; 4 doi: 10.3402/iee.v4.23011.
35. Wright E, Temperton NJ, Marston DA, et al. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J Gen Virol 2008; 89(Pt 9): 2204-13.
36. Gierer S, Hofmann-Winkler H, Albuali WH, et al. Lack of MERS coronavirus neutralizing antibodies in humans, eastern province, Saudi Arabia. Emerg Infect Dis 2013; 19(12): 2034-6.
37. Hemida MG, Perera RA, Wang P, et al. Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill 2013; 18(50): 20659.
38. Raj VS, Osterhaus AD, Fouchier RA, et al. MERS: emergence of a novel human coronavirus. Curr Opin Virol 2014; 5: 58-62.
39. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe - Preliminary Report. N Engl J Med 2015; doi: 10.1056/NEJMoa1502924.
40. Szecsi J, Boson B, Johnsson P, et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J 2006; 3: 70.
41. Ryder AB, Buonocore L, Vogel L, et al. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. J Virol 2015; 89(5): 2820-30.
42. Kapadia SU, Simon ID, Rose JK. SARS vaccine based on a replication- defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology 2008; 376(1): 165-72.
43. Matassov D, Marzi A, Latham T, et al. Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of ebola virus. J Infect Dis 2015; 212 (Suppl 2): S443-51.
44. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386(9996): 857-66.
45. Wong G, Qiu X, Ebihara H, et al. Characterization of a bivalent vaccine capable of inducing protection against both ebola and cross-clade H5N1 influenza in mice. J Infect Dis 2015; 212 (Suppl 2): S435-42.
46. Cooper D, Wright KJ, Calderon PC, et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 2008; 82(1): 207-19.
47. Berlioz-Torrent C, Shacklett BL, Erdtmann L, et al. Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J Virol 1999; 73(2): 1350-61.
48. Carnec X, Ermonval M, Kreher F, et al. Role of the cytosolic tails of Rift Valley fever virus envelope glycoproteins in viral morphogenesis. Virology 2014; 448: 1-14.
49. Day JR, Munk C, Guatelli JC. The membrane-proximal tyrosinebased sorting signal of human immunodeficiency virus type 1 gp41 is required for optimal viral infectivity. J Virol 2004; 78(3): 1069-79.
50. Freed EO, Martin MA. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol 1996; 70(1): 341-51.
51. Christodoulopoulos I, Cannon PM. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. J Virol 2001; 75(9): 4129-38.
52. Hohne M, Thaler S, Dudda JC, et al. Truncation of the human immunodeficiency virus-type-2 envelope glycoprotein allows efficient pseudotyping of murine leukemia virus retroviral vector particles. Virology 1999; 261(1): 70-8.
53. Fukushi S, Mizutani T, Saijo M, et al. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol 2005; 86(Pt 8): 2269-74.
54. Fukuma A, Tani H, Taniguchi S, et al. Inability of rat DPP4 to allow MERS-CoV infection revealed by using a VSV pseudotype bearing truncated MERS-CoV spike protein. Arch Virol 2015; 160(9): 2293-300.
55. Buonocore L, Blight KJ, Rice CM, et al. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol 2002; 76(14): 6865-72.
56. Pasqual G, Rojek JM, Masin M, et al. Old world arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport. PLoS Pathog 2011; 7(9): e1002232.
57. Shtanko O, Nikitina RA, Altuntas CZ, et al. Crimean-Congo hemorrhagic fever virus entry into host cells occurs through the multivesicular body and requires ESCRT regulators. PLoS Pathog 2014; 10(9): e1004390.
58. Empig CJ, Goldsmith MA. Association of the caveola vesicular system with cellular entry by filoviruses. J Virol 2002; 76(10): 5266-70.
59. Bhattacharyya S, Warfield KL, Ruthel G, et al. Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology 2010; 401(1): 18-28.
60. Mulherkar N, Raaben M, de la Torre JC, et al. The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology 2011; 419(2): 72-83.
61. Saeed MF, Kolokoltsov AA, Albrecht T, et al. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog 2010; 6(9): e1001110.
62. Nanbo A, Imai M, Watanabe S, et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoproteindependent manner. PLoS Pathog 2010; 6(9): e1001121.
63. Aleksandrowicz P, Marzi A, Biedenkopf N, et al. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J Infect Dis 2011; 204 (Suppl 3): S957-67.
64. Modis Y. Class II fusion proteins. Adv Exp Med Biol 2013; 790: 150-66.
65. Porta J, Jose J, Roehrig JT, et al. Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies. J Virol 2014; 88(17): 9616-23.
66. Fox JM, Long F, Edeling MA, et al. Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell 2015; 163(5): 1095-107.
67. Jin J, Liss NM, Chen DH, et al. Neutralizing monoclonal antibodies block chikungunya virus entry and release by targeting an epitope critical to viral pathogenesis. Cell Rep 2015; 13(11): 2553-64.
68. Hu D, Zhang J, Wang H, et al. Chikungunya virus glycoproteins pseudotype with lentiviral vectors and reveal a broad spectrum of cellular tropism. PLoS One 2014; 9(10): e110893.
69. Burt FJ, Swanepoel R, Shieh WJ, et al. Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med 1997; 121(8): 839-46.
70. Takada A, Robison C, Goto H, et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci USA 1997; 94(26): 14764-9.
71. Chan SY, Speck RF, Ma MC, et al. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol 2000; 74(10): 4933-7.
72. MacKenzie TC, Kobinger GP, Kootstra NA, et al. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol Ther 2002; 6(3): 349-58.
73. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197(5): 633-42.
74. Matsuura Y, Tani H, Suzuki K, et al. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 2001; 286(2): 263-75.
75. Wang W, Butler EN, Veguilla V, et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods 2008; 153(2): 111-9.
76. Guo Y, Rumschlag-Booms E, Wang J, et al. Analysis of hemagglutinin- mediated entry tropism of H5N1 avian influenza. Virol J 2009; 6: 39.
77. Muller MA, Raj VS, Muth D, et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 2012; 3(6). e00515-12.
78. Grehan K, Ferrara F, Temperton N. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX 2015; 2: 379-84.
79. Negrete OA, Levroney EL, Aguilar HC, et al. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 2005; 436(7049): 401-5.
80. Kahl CA, Pollok K, Haneline LS, et al. Lentiviral vectors pseudotyped with glycoproteins from Ross River and vesicular stomatitis viruses: variable transduction related to cell type and culture conditions. Mol Ther 2005; 11(3): 470-82.
81. Simmons G, Reeves JD, Rennekamp AJ, et al. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci USA 2004; 101(12): 4240-5.
82. Han DP, Kim HG, Kim YB, et al. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology 2004; 326(1): 140-9.
83. Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol 2005; 79(23): 14614-21.